Name | Alniditan dihydrochloride |
---|
Description | Alniditan (Alnitidan) dihydrochloride is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK 293 cells, respectively. Alniditan dihydrochloride has migraine-preventive effects[1][2]. |
---|---|
Related Catalog | |
Target |
human 5-HT1B Receptor:1.7 nM (IC50) human 5-HT1D Receptor:1.3 nM (IC50) 5-HT1B Receptor:0.9 nM (Kd) 5-HT1D Receptor:1.2 nM (Kd) |
In Vitro | In vitro, Alniditan exhibits little vasoconstrictive effects on the rat basilar artery, although at a very high concentration 1 mM, Alniditan causes intensive constriction, most likely through a mechanism independent from 5-HT receptor activation[1]. |
In Vivo | The intraperitoneal administration of Alniditan ED50=9 μg/kg dose dependly reduces [125I]-BSA extravasation in the rat meninges when done 30 min before stimulation. Alniditan dose dependently attenuateds the neurogenic inflammation in vivo model of neurogenic inflammation[1]. |
References |
Molecular Formula | C17H28Cl2N4O |
---|---|
Molecular Weight | 375.34 |